Abstract Details

Title Validation Of Brief International Cognitive Assessment For Multiple Sclerosis In Tunisia

Topic Multiple Sclerosis

Presentation(s) P10 - Poster Session 10 (5:30 PM-6:30 PM)

Poster/Presentation
Number 9-016

Objective The goal of this study was to validate the Tunisian version of the Brief International Cognitive Assessment of Multiple Sclerosis (BICAMS) in a cohort of MS patients.

Background

The BICAMS is a cognitive battery evaluating patients diagnosed with Multiple Sclerosis (MS) independently from their ethnic origin.

Design/Methods A prospective study was conducted in the department of neurology in Razi Hospital between March and September 2019 including patients diagnosed with MS according to 2017 McDonald criteria, and matched with healthy controls according to age, sex, and educational level. The BICAMS is divided into three parts. The first one evaluates the information processing speed: Symbol Digit Modalities Test (SDMT). The second one assesses the verbal memory: TVLT (Tunisian Verbal Learning Test - 12 words). The third one evaluates the visuo-spatial memory: BVMT (Brief Verbal Memory Test). In the MS group, disease subtype, expanded disability status scale (EDSS) and disease duration were also noted. All p values <0.05 were considered to be statistically significant.

Results Forty-four cases of MS were compared with forty-four healthy controls (sex-ratio F/H= 3.4, and mean age =34 years±10 for both patients and controls). Mean EDSS score was 3. Subjects with MS had lower performances for all tests: SDMT (37 versus 46; p=0.009), BVMT (21 versus 26; p=0.011), and TVLT (42 versus 46; p=0.011). Cognitive impairment was found in 74% of cases. Low educational levels, progressive MS, EDSS score>4, and MS duration more than ten years were associated with lower performances in SDMT, BVMT and TVLT (p<0.05).

Conclusions

The Tunisian version of the BICAMS was reliable for the evaluation of information processing speed, visual memory and verbal memory in Tunisian MS patients.

Authors/Disclosures
Saloua Mrabet, MD (Razi University Hospital) PRESENTER	Dr. Mrabet has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Ben Djebara Mouna	No disclosure on file
Imen Kacem, MD (Department of Neurology)	Dr. Kacem has nothing to disclose.
Riadh Gouider, MD, F�鶹��ýӳ�� (Erazi Hospital)	Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hikma. The institution of Dr. Gouider has received research support from Clinical Investigation Center. The institution of Dr. Gouider has received research support from Menactrims.

�鶹��ýӳ��

�鶹��ýӳ��